CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers

Federica Turdo, Francesca Bianchi, Patrizia Gasparini, Marco Sandri, Marianna Sasso, Loris De Cecco, Luca Forte, Patrizia Casalini, Piera Aiello, Lucia Sfondrini, Roberto Agresti, Maria Luisa Carcangiu, Ilaria Plantamura, Gabriella Sozzi, Elda Tagliabue, Manuela Campiglio

Research output: Contribution to journalArticlepeer-review

Abstract

CDCP1, a transmembrane noncatalytic receptor, the expression of which has been associated with a poor prognosis in certain epithelial cancers, was found to be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, in which it promoted aggressive activities-ie, migration, invasion, anchorage-independent tumor growth, and the formation of vascular-like structures in vitro. By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number synergized with nodal (N) status in determining disease-free and distant disease-free survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC and FISH and lymph node positivity in predicting relapse did not differ significantly, indicating that CDCP1 overexpression in human primary TNBCs, regardless of being driven by gains in CDCP1, is for a critical factor in the progression of N-positive TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and a potential therapeutic target.

Original languageEnglish
Pages (from-to)69649-69665
Number of pages17
JournalOncotarget
Volume7
Issue number43
DOIs
Publication statusPublished - 2016

Keywords

  • CDCP1
  • CDCP1 copy number
  • Metastasis
  • Prognosis
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers'. Together they form a unique fingerprint.

Cite this